Pfizer in Another Showdown With the U.S. Department of Treasury

If nothing else, Pfizer is extremely diligent about anything involving taxes.

The big drug maker, which raised a national ruckus by pursuing acquisitions designed to lower its tax rate, has engaged in another showdown of sorts with the US Department of Treasury. The latest dispute however, involves decidedly lower stakes — nearly $8.3 million in interest that Pfizer claims it’s owed on a $500 million overpayment that was noted on its 2008 tax return.

Back to news